Gilead Sciences PT Raised to $162 After Q4 Revenue Rose 5% to $7.9B
BofA raised its Gilead Sciences price target to $162 from $154 and kept a Buy rating after fiscal Q4 revenue rose 5% to $7.9 billion. Analysts no longer model Yeztugo cannibalizing Descovy in 2026, citing momentum from the twice-yearly HIV prevention therapy and continued strength in Biktarvy and liver disease sales.
1. Price Target Hike
BofA increased its price target on Gilead Sciences to $162 from $154 while affirming a Buy rating, driven by robust fiscal Q4 dynamics and confidence in the company’s product pipeline.
2. Q4 Financial Results
Gilead reported fiscal Q4 revenue of $7.9 billion, up 5% year-over-year, led by HIV and liver disease products, partly offset by lower COVID-19 therapy (Veklury) sales.
3. Updated 2026 Outlook
Analysts removed assumptions of Yeztugo cannibalizing Descovy sales in 2026 after the successful launch of the twice-yearly HIV prevention therapy, and they expect continued momentum in Biktarvy and other core franchises.